Chronic migraine - Classification, characteristics and treatment

Nature Reviews Neurology

Volumn 8, Issue 3, 2012, Pages 162-171

  Diener, Hans Christoph ^a   Dodick, David W ^b   Goadsby, Peter J ^c   Lipton, Richard B ^d   Olesen, Jes ^e   Silberstein, Stephen D ^f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MAYO CLINIC HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; ETIRACETAM; PLACEBO; SAFFLOWER EXTRACT; TOPIRAMATE; VALPROIC ACID;

ACUPUNCTURE; BEHAVIOR MODIFICATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; NAUSEA; NERVE STIMULATION; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; TRANSFORMED MIGRAINE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

CHRONIC DISEASE; HUMANS; MIGRAINE DISORDERS;

EID: 84858153666     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.13     Document Type: Review

References (94)

1. D'Amico, D. et al. Quality of life and disability in primary chronic daily headaches. Neurol. Sci. 24 (Suppl. 2), S97-S100 (2003).
2. Dodick, D. W. Clinical practice. Chronic daily headache. N. Engl. J. Med. 354, 158-165 (2006).
3. Wiendels, N. J. et al. Chronic frequent headache in the general population: comorbidity and quality of life. Cephalalgia 26, 1443-1450 (2006).
4. Monzón, M. J. & Láinez, M. J. Quality of life in migraine and chronic daily headache patients. Cephalalgia 18, 638-643 (1998).
5. Meletiche, D. M., Lofland, J. H. & Young, W. B. Quality-of-life differences between patients with episodic and transformed migraine. Headache 41, 573-578 (2001).
6. Wang, S. J., Fuh, J. L., Lu, S. R. & Juang, K. D. Outcomes and predictors of chronic daily headache in adolescents: a 2-year longitudinal study. Neurology 68, 591-596 (2007).
7. Guitera, V., Muñoz, P., Castillo, J. & Pascual, J. Quality of life in chronic daily headache: a study in a general population. Neurology 58, 1062-1065 (2002).
8. D'Amico, D. et al. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache 45, 553-560 (2005).
9. Lipton, R. B. et al. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23, 441-450 (2003).
10. Bigal, M. E., Serrano, D., Reed, M. & Lipton, R. B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71, 559-566 (2008).
11. Munakata, J. et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 49, 498-508 (2009).
12. Mathew, N. T., Stubits, E. & Nigam, M. Transformation of episodic migraine into daily headache: analysis of factors. Headache 22, 66-68 (1982).
13. st edn (eds Diener, H. C. & Wilkinson, M.) 5-8 (Springer-Verlag Berlin and Heidelberg, New York, 1988).
14. Gowers, W. R. A Manual of Diseases of the Nervous System (P. Blakiston, Son & Co., Philadelphia, 1888).
15. Sjaastad, O. "Chronic daily headache" ("cefalea cronica quotidiana"). Cephalalgia 5 (Suppl. 2), 191-193 (1985).
16. Mathew, N. T. Drug induced refractory headache clinical features and management [abstract 52]. Headache 27, 305-306 (1987).
17. [No authors listed]. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 8 (Suppl. 7), 1-96 (1988).
18. Stovner, L. J., Zwart, J. A., Hagen, K., Terwindt, G. M. & Pascual, J. Epidemiology of headache in Europe. Eur. J. Neurol. 13, 333-345 (2006).
19. Stovner, L. J. et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27, 193-210 (2007).
20. Headache Classification Committee et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742-746 (2006).
21. Manzoni, G. C. et al. Chronic migraine classification: current knowledge and future perspectives. J. Headache Pain 12, 585-592 (2011).
22. Saper, J. R. The mixed headache syndrome: a new perspective. Headache 22, 284-286 (1982).
23. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA 179, 717-718 (1962).
24. Silberstein, S. D. & Lipton, R. B. in Headache Ch. 12 (eds Goadsby, P. J. & Silberstein, S. D.) 201-225 (Butterworth-Heinemann, Boston, 1997).
25. Silberstein, S. D., Lipton, R. B., Solomon, S. & Mathew, N. T. Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache 34, 1-7 (1994).
26. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 (Suppl. 1), 9-160 (2004).
27. Yoon, M. S., Obermann, M., Dommes, P., Diener, H. C. & Katsarava, Z. Prevalence of migraine in a population based sample in Germany: results of the GHC study [abstract PO116]. Cephalalgia 29 (1 Suppl.), 56-57 (2009).
28. Zeeberg, P., Olesen, J. & Jensen, R. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria. Cephalalgia 29, 214-220 (2009).
29. Bigal, M., Rapoport, A., Sheftell, F., Tepper, S. & Lipton, R. The International Classification of Headache Disorders revised criteria for chronic migraine - field testing in a headache specialty clinic. Cephalalgia 27, 230-234 (2007).
30. Mathew, N. T. Transformed migraine. Cephalalgia 13 (Suppl. 12), 78-83 (1993).
31. Silberstein, S. D., Lipton, R. B. & Sliwinski, M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 47, 871-875 (1996).
32. Natoli, J. L. et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 30, 599-609 (2010).
33. Linde, M., Stovner, L. J., Zwart, J. A. & Hagen, K. Time trends in the prevalence of headache disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). Cephalalgia 31, 585-596 (2011).
34. Scher, A. I., Stewart, W. F., Ricci, J. A. & Lipton, R. B. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106, 81-89 (2003).
35. Bigal, M. E. & Lipton, R. B. Concepts and mechanisms of migraine chronification. Headache 48, 7-15 (2008).
36. Bigal, M. E. et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48, 1157-1168 (2008).
37. Bigal, M. E. & Lipton, R. B. Excessive opioid use and the development of chronic migraine. Pain 142, 179-182 (2009).
38. Bigal, M. E. & Lipton, R. B. Overuse of acute migraine medications and migraine chronification. Curr. Pain. Headache Rep. 13, 301-307 (2009).
39. Manack, A., Buse, D. C., Serrano, D., Turkel, C. C. & Lipton, R. B. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 76, 711-718 (2011).
40. Goadsby, P. J., Charbit, A. R., Andreou, A. P., Akerman, S. & Holland, P. R. Neurobiology of migraine. Neuroscience 161, 327-341 (2009).
41. Burstein, R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89, 107-110 (2001).
42. Goadsby, P. J. & Hargreaves, R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache 48, 799-804 (2008).
43. Zagami, A. S. & Lambert, G. A. Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. Exp. Brain Res. 81, 552-566 (1990).
44. Shields, K. G. & Goadsby, P. J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128, 86-97 (2005).
45. Andreou, A. P., Shields, K. G. &Goadsby, P. J. GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol. Dis. 37, 314-323 (2010).
46. Weiller, C. et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1, 658-660 (1995).
47. Afridi, S. K. et al. A positron emission tomographic study in spontaneous migraine. Arch. Neurol. 62, 1270-1275 (2005).
48. Bahra, A., Matharu, M. S., Buchel, C., Frackowiak, R. S. & Goadsby, P. J. Brainstem activation specific to migraine headache. Lancet 357, 1016-1017 (2001).
49. Matharu, M. S. et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127, 220-230 (2004).
50. Welch, K. M., Nagesh, V., Aurora, S. K. & Gelman, N. Periaqueductal grey matter dysfunction in migraine: cause or the burden of illness? Headache 41, 629-637 (2001).
51. Moulton, E. A. et al. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS ONE 3, e3799 (2008).
52. Bouhassira, D., Bing, Z. & Le Bars, D. Studies of the brain structures involved in diffuse noxious inhibitory controls: the mesencephalon. J. Neurophysiol. 64, 1712-1723 (1990).
53. Aurora, S. K. Is chronic migraine one end of a spectrum of migraine or a separate entity? Cephalalgia 29, 597-605 (2009).
54. Aurora, S. K. Spectrum of illness: understanding biological patterns and relationships in chronic migraine. Neurology 72 (5 Suppl.), S8-S13 (2009).
55. Limmroth, V., Katsarava, Z., Fritsche, G., Przywara, S. & Diener, H. C. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59, 1011-1014 (2002).
56. Zeeberg, P., Olesen, J. & Jensen, R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 66, 1894-1898 (2006).
57. De Felice, M. & Porreca, F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 29, 1277-1284 (2009).
58. De Felice, M. et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann. Neurol. 67, 325-337 (2010).
59. Diener, H. C, et al. Integrated headache care. Cephalalgia 31, 1039-1047 (2011).
60. Antonaci, F., Dumitrache, C., De Cillis, I. & Allena, M. A review of current European treatment guidelines for migraine. J. Headache Pain 11, 13-19 (2010).
61. British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache and medication-overuse headache. BASH [online], http://217.174.249.183/upload/NS-BASH/2010-BASH-Guidelines.pdf (2010).
62. Rains, J. C. & Penzien, D. B. Behavioral treatment strategies for migraine and tension-type headache: a review of the evidence and future directions. Expert Rev. Neurother. 2, 749-760 (2002).
63. Gallai, V., Sarchielli, P. for the Ad Hoc Committee for the Diagnostic and Therapeutic Guidelines of Migraine and Cluster Headache. Diagnostic and therapeutic guidelines for migraine. Italian Society for the Study of Headaches (SISC). J. Headache Pain 2 (Suppl. 1), S125-S129 (2001).
64. Silberstein, S. D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommitee of the American Academy of Neurology. Neurology 55, 754-762 (2000).
65. Evers, S. et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur. J. Neurol. 16, 968-981 (2009).
66. Yurekli, V. A. et al. The effect of sodium valproate on chronic daily headache and its subgroups. J. Headache Pain 9, 37-41 (2008).
67. Silvestrini, M. et al. Topiramate in the treatment of chronic migraine. Cephalalgia 23, 820-824 (2003).
68. Diener, H. C. et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27, 814-823 (2007).
69. Silberstein, S. D. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47, 170-180 (2007).
70. Diener, H. C. et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 29, 1021-1027 (2009).
71. Foster, L., Clapp, L., Erickson, M. & Jabbari, B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56, 1290-1293 (2001).
72. Mathew, N. T. et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45, 293-307 (2005).
73. Ranoux, D., Attal, N., Morain, F. & Bouhassira, D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64, 274-283 (2008).
74. Freitag, F. G., Diamond, S., Diamond, M. & Urban, G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 48, 201-209 (2008).
75. Aoki, K. R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26, 785-793 (2005).
76. Gazerani, P., Staahl, C., Drewes, A. M. & Arendt-Nielsen, L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122, 315-325 (2006).
77. Bergerot, A. et al. Animal models of migraine: looking at the component parts of a complex disorder. Eur. J. Neurosci. 24, 1517-1534 (2006).
78. Silberstein, S., Mathew, N., Saper, J. & Jenkins, S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40, 445-450 (2000).
79. Evers, S. et al. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 24, 838-843 (2004).
80. Silberstein, S. D. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 80, 1126-1137 (2005).
81. Aurora, S. K., Gawel, M., Brandes, J. L., Pokta, S. & Vandenburgh, A. M. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47, 486-499 (2007).
82. Saper, J. R., Mathew, N. T., Loder, E. W., DeGryse, R. & VanDenburgh, A. M. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med. 8, 478-485 (2007).
83. Vo, A. H. et al. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Aviat. Space Environ. Med. 78 (5 Suppl.), B113-B118 (2007).
84. Dodick, D. W. et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45, 315-324 (2005).
85. Aurora, S. K. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30, 793-803 (2010).
86. Diener, H.C. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30, 804-814 (2010).
87. Dodick, D. W. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50, 921-936 (2010).
88. Beran, R. G. & Spira, P. J. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia 31, 530-536 (2011).
89. Saper, J. R. et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31, 271-285 (2011).
90. Lipton, R. B. et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine [abstract PO47]. Cephalalgia 29 (1 Suppl.), 30 (2009).
91. Nicholson, R. A., Buse, D. C., Andrasik, F. & Lipton, R. B. Nonpharmacologic treatments for migraine and tension-type headache: how to choose and when to use. Curr. Treat. Options Neurol. 13, 28-40 (2011).
92. Coeytaux, R. R. et al. A randomized, controlled trial of acupuncture for chronic daily headache. Headache 45, 1113-1123 (2005).
93. Park, J. M., Park, S. U., Jung, W. S. & Moon, S. K. Carthami-Semen acupuncture point injection for chronic daily headache: a pilot, randomised, double-blind, controlled trial. Complement. Ther. Med. 19 (Suppl. 1), S19-S25 (2011).
94. Calhoun, A. H. & Ford, S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache 47, 1178-1183 (2007).